Objective: To determine the effect of albendazole on the viability of protoscolexes and the frequency of relapses of echinococcal liver disease. Methods: The study was conducted in the surgical department of the multidisciplinary clinic of the Samarkand State Medical University, for 4 years from 2014 to 2017, with further follow-up for 5 years. The study included 86 cases in the age group of 17-66 years. The patients were divided into two groups of 43 people each. In the comparison group, patients were directly operated on, while in the main group, patients were prescribed albendazole for 12 weeks before surgery, followed by a postoperative course for 12 weeks. Results: Among patients treated with albendazole, no patient had viable cysts at the time of surgery compared to 93.1% of patients who did not receive albendazole before surgery (P<0.01). In patients not treated with albendazole, the relapse rate was 18.6%, while in patients treated with albendazole, no relapse was observed (P≤0.05). Conclusions: We concluded that albendazole is an effective adjuvant therapy in the treatment of Echinococcal liver disease.